



Rani Therapeutics Appoints Jean-Luc Butel and Lauren DeBuono to Board of Directors

June 28, 2021

San Jose, CA | June 28, 2021 08:00 AM Pacific Daylight Time

Rani Therapeutics, a disrupter in oral biologics, today announced the appointment of Jean-Luc Butel and Lauren DeBuono to its Board of Directors. These new Directors bring a wide range of private and public company leadership experience at healthcare, technology and consumer companies.

Jean-Luc Butel has served as a healthcare executive for more than 30 years and is a well-respected global healthcare advisor. Currently, Mr. Butel serves on various boards at Takeda, Novo Holdings, and SG Innovate, in addition to several healthcare startups in both Asia and Europe. Previously, Mr. Butel served on the board of Varian Medical Systems, the Economic Development Board (EDB) of Singapore, as a senior advisor to McKinsey's healthcare practice and as an advisor for Singapore's National Research Foundation. He worked in senior executive positions with Johnson & Johnson, Becton Dickinson, Medtronic and Baxter International. Mr. Butel received his B.A. from The George Washington University and an M.B.A. from the Thunderbird School of International Management.

Lauren DeBuono is a seasoned executive who spent most of her career in long-term, complex Chief Operating Officer and Chief Financial Officer roles at mid and large sized healthcare and consumer-facing companies. Ms. DeBuono has also served as President, Chief Executive Officer, and General Counsel for various private and public companies across multiple sectors. Currently, she is a Managing Partner at FLG Partners, focusing on interim CEO, CFO, and Board advisory services, as well as executive coaching. Additionally, Ms. DeBuono has served on several public company Board of Directors, including Cadence Pharmaceuticals, VISX, and InVivo, and was the Audit Chair at both VISX and InVivo. Ms. DeBuono received her B.A. from Duke University, an M.A. from Stanford University, and a J.D. from New York University School of Law.

"On behalf of Rani Therapeutics, I would like to welcome Jean-Luc and Lauren as members of our Board," said Talat Imran, Rani's Chief Executive Officer. "We look forward to benefiting from their deep and diverse executive experience."

"Rani Therapeutics has developed what I believe to be a highly differentiated biologics delivery platform that has the potential to replace subcutaneous and intravenous injections," said Jean-Luc Butel. "I look forward to working closely with Rani's executive leadership team and the rest of the Board as we execute on the company's goal to deliver the RaniPill™ technology to patients worldwide."

"I am delighted to be joining Rani Therapeutics and excited by the company's innovative RaniPill™ technology," said Lauren DeBuono. "I hope to leverage my experience to help guide Rani through its next phases of development, including the anticipated clinical progression of its drug candidates and their potential commercialization."

About Rani Therapeutics

Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. The company has developed the RaniPill™ capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani has conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule.

Investor Contact:

investors@ranitherapeutics.com

Contact Details

Media Contact:

media@ranitherapeutics.com